Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

EVOK Evoke Pharma Inc

0,475

0,044 (10,21%)

01 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form ARS/A - Annual Report to Security Holders: [Amend]

Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Evoke Pharma Charts.

Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Evoke Pharma Charts.

News Evoke Pharma Inc

Form 3 - Initial statement of beneficial ownership of securities
Freitag 31 Mai 2024 (2 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 24 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 24 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 24 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference
Donnerstag 16 Mai 2024 (2 Wochen vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 14 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Evoke Pharma Reports First Quarter 2024 Financial Results
Dienstag 14 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 14 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Dienstag 14 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 14 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
Mittwoch 17 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
Donnerstag 21 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Weitere Evoke Pharma Inc News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen